
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Acute Liver Failure Guidelines</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Acute Liver Failure Guidelines</strong></summary>
            <div>
                <ul><li>Official practice recommendations from the American College of Gastroenterology (ACG).</li><li>Published in The American Journal of Gastroenterology 118(7):p 1128-1153, July 2023.</li><li>DOI: 10.14309/ajg.0000000000002340.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of patients with Acute Liver Failure (ALF) due to acetaminophen toxicity typically require liver transplantation?</li><li>2. Which prognostic scoring system is generally more accurate for acetaminophen-associated ALF versus non-acetaminophen-associated ALF?</li><li>3. What is the recommended first-line vasopressor for hypotension refractory to fluid resuscitation in patients with ALF?</li><li>4. What is the approximate incidence of Acute Liver Failure in developed countries per million population?</li><li>5. In patients with ALF and grade 2 or higher encephalopathy, what early intervention is suggested for hyperammonemia, even without conventional renal replacement therapy indications?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction &amp; Definition of Acute Liver Failure (ALF)</strong></summary>
            <div>
                <ul><li>ALF is a rare, acute, potentially reversible condition.</li><li>Characterized by liver injury (abnormal liver tests), coagulopathy (INR &gt;1.5), and hepatic encephalopathy (HE).</li><li>Occurs in patients w/o preexisting liver disease, leading to severe liver impairment &amp; rapid clinical deterioration.</li></ul>
                
        <details>
            <summary><strong>Key Characteristics</strong></summary>
            <div>
                <ul><li>Illness duration &lt;26 weeks.</li><li>No preexisting liver disease or cirrhosis (exceptions: AIH, Budd-Chiari, Wilson disease).</li><li>Any degree of mental status alteration (encephalopathy).</li><li>Coagulopathy: INR ≥1.5.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>O&#x27;Grady Classification of ALF Presentation</strong></summary>
            <div>
                <ul><li>Differentiates based on rapidity of HE onset.</li><li>Utility of acute/subacute categories can be less useful in clinical management due to overlap.</li></ul>
                
        <details>
            <summary><strong>Hyperacute ALF</strong></summary>
            <div>
                <ul><li>Predominantly seen in viral hepatitis A/E, acetaminophen (APAP) toxicity, ischemic injury.</li><li>High risk of cerebral edema (CE).</li><li>Best prognosis w/o transplantation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Acute ALF</strong></summary>
            <div>
                <ul><li>Can be seen in hepatitis B virus (HBV) infection.</li><li>Lower risk of CE than hyperacute.</li><li>Poorer outcome w/o transplantation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Subacute ALF</strong></summary>
            <div>
                <ul><li>More often seen w/ non-APAP drug-induced liver injury.</li><li>Lower risk of CE than hyperacute.</li><li>Poorer outcome w/o transplantation.</li><li>Care must be taken not to mistake for chronic liver failure.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Etiology of ALF</strong></summary>
            <div>
                <ul><li>Varies geographically; essential for prognosis &amp; treatment strategy (esp. LT necessity).</li><li>Independent predictor of waitlist mortality, not post-LTx outcomes.</li><li>Waitlist mortality &amp; spontaneous survival for DILI, AIH, HBV were ↓ than for acetaminophen toxicity.</li></ul>
                
        <details>
            <summary><strong>Common Causes</strong></summary>
            <div>
                <ul><li>North America, Japan, Europe: Drug-induced liver injury (DILI), viral hepatitis, cryptogenic (indeterminate) liver failure.</li><li>Developing countries: Acute viral hepatitis (AVH) remains predominant etiology.</li></ul>
                
        <details>
            <summary><strong>Indeterminate ALF</strong></summary>
            <div>
                <ul><li>Percentage varies globally: 5%–70%.</li><li>Substantial proportion may be due to unidentified viral infection or underrecognized AIH.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>ALF vs. Other Liver Conditions</strong></summary>
            <div>
                <ul><li>Crucial to distinguish ALF from acutely decompensated cirrhosis or acute on chronic liver failure (ACLF).</li><li>Management differs significantly.</li></ul>
                
        <details>
            <summary><strong>Acutely Decompensated Cirrhosis</strong></summary>
            <div>
                <ul><li>Much more likely in hospitalized patients w/ liver failure.</li><li>Generally easily distinguishable from true ALF.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Acute on Chronic Liver Failure (ACLF)</strong></summary>
            <div>
                <ul><li>Presents w/ acutely decompensated cirrhosis; very high short-term (&lt;28 days) mortality.</li><li>Develops in cirrhosis w/ superimposed liver injury → profound systemic inflammation (e.g., viral infection, DILI, alcohol-associated hepatitis, bacterial infection).</li><li>Characterized by: intense systemic inflammation, close temporal relationship to precipitating events, single- or multiple-organ failure.</li></ul>
                
        <details>
            <summary><strong>Distinguishing Features (ALF vs. ACLF)</strong></summary>
            <div>
                <ul><li>ALF: No prior liver disease, acute onset, often younger patients, high potential for LT.</li><li>ACLF: Preexisting cirrhosis, acute decompensation, older patients, often multiple organ failures, LT more complex.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>ALF remains rare; incidence data not robust.</li><li>Studies limited by cohorts, patient population source, or single-cause inclusion.</li><li>Data often tainted by inaccurate coding of decompensated cirrhosis or ACLF as ALF.</li></ul>
                
        <details>
            <summary><strong>Incidence Rates</strong></summary>
            <div>
                <ul><li>Developed countries: ≈1–6 cases per million population.</li><li>United States: ≈2,000–3,000 cases per year.</li><li>UK &amp; Scotland: Up to 0.8 per 100,000 person-years (PY) &amp; ≈0.62 per 100,000 PY, respectively.</li><li>Germany (state-insured cohort): Up to 1.13 per 100,000 PY.</li><li>US-based health system (drug-induced ALF): 0.161 per 100,000 PY.</li><li>Higher in Taiwan (8.02 per 100,000 PY) &amp; Thailand (6.29 per 100,000 PY).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Economic Burden &amp; Research Gaps</strong></summary>
            <div>
                <ul><li>Less data exist on economic burden.</li><li>Few controlled clinical trials on management.</li><li>Guidelines predominantly based on expert opinion, not evidence-based medicine, due to lack of solid data.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>General Management</strong></summary>
            <div>
                <ul><li>Focus on distinguishing acute from chronic/acute-on-chronic liver failure.</li><li>Early recognition &amp; timely referral to a liver transplant center are critical for potentially lifesaving treatment &amp; transplant considerations.</li></ul>
                
        <details>
            <summary><strong>Initial Assessment &amp; Diagnostic Evaluation</strong></summary>
            <div>
                <ul><li>Comprehensive history: symptom timeline, chronic liver disease, alcohol, viral risk factors, medication review (Rx, OTC, CAM).</li><li>Contact next of kin if patient history unobtainable.</li><li>Thorough physical exam: vital signs, jaundice, signs of chronic liver disease, mental status assessment.</li></ul>
                
        <details>
            <summary><strong>Hepatic Encephalopathy (HE) Grading</strong></summary>
            <div>
                <ul><li>Type A HE graded by West-Haven Criteria.</li><li>Grade 2 encephalopathy → transfer to ICU.</li><li>Grades 3 &amp; 4 HE → consider intubation for airway protection.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Coagulopathy Assessment</strong></summary>
            <div>
                <ul><li>Assessed in every patient.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Laboratory &amp; Diagnostic Workup</strong></summary>
            <div>
                <ul><li>Initial labs: CBC, electrolytes, LFTs, INR, PTT, ammonia, glucose, lactate, ABG, viral hepatitis serologies (A, B, C, E), HIV, autoimmune markers (ANA, ASMA, IgG), ceruloplasmin, alpha-1 antitrypsin, toxicology screen (urine/serum), APAP level, pregnancy test.</li><li>Imaging: Abdominal ultrasound w/ Doppler, CT/MRI abdomen.</li><li>Special tests: Urine ethyl glucuronide or serum phosphatidyl ethanol (PETH) for alcohol suspicion.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Imaging Studies</strong></summary>
            <div>
                <ul><li>Help identify underlying chronic liver disease/ACLF (shrunken liver, regenerative nodules, irregular surface).</li><li>Liver may appear shrunken in ALF due to massive collapse.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Alcohol-Induced Liver Disease</strong></summary>
            <div>
                <ul><li>Chronic alcohol consumption adversely affects outcomes.</li><li>Biomarkers (ethyl glucuronide or PETH) should be used + psychosocial assessment.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concepts: Initial Assessment</strong></summary>
            <div>
                <ul><li>Comprehensive testing to elucidate diagnosis &amp; exclude underlying chronic liver disease is essential.</li><li>Biomarkers (ethyl glucuronide or PETH) should be used in addition to psychosocial assessment when alcohol-induced liver disease is suspected.</li><li>Grade 2 encephalopathy → prompt transfer to ICU; intubation for airway protection considered for grades 3 &amp; 4 HE.</li><li>Referral for hepatology/gastroenterology consultation ASAP after ALF identification.</li><li>Early communication w/ transplant center is crucial.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Liver Biopsy</strong></summary>
            <div>
                <ul><li>Can help diagnose ALF etiology &amp; predict outcomes in selected patients.</li><li>Helps rule out infiltrative disease/malignancy &amp; identify contraindications to LT.</li><li>Can aid in AIH diagnosis, which may respond to immunosuppressive therapy, potentially sparing LT.</li></ul>
                
        <details>
            <summary><strong>Safety &amp; Efficacy</strong></summary>
            <div>
                <ul><li>Concerns exist regarding risks in coagulopathic patients (bleeding, organ perforation, sepsis, death).</li><li>Small observational studies suggest transjugular liver biopsy (TJLB) is safe &amp; effective.</li><li>Mini laparoscopy w/ liver biopsy also safe but not widely available.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>TJLB vs. Other Methods</strong></summary>
            <div>
                <ul><li>TJLB is frequently used.</li><li>Despite smaller sample, TJLB valuable in determining hepatocellular necrosis, which predicts higher death rate in non-APAP ALF.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concepts: Liver Biopsy</strong></summary>
            <div>
                <ul><li>Liver biopsy may help exclude infiltrative disease/malignancy &amp; identify LT contraindications.</li><li>Liver biopsy may help diagnose AIH, which may respond to immunosuppressive therapy.</li><li>Insufficient evidence to recommend routine use in other settings.</li><li>Suggest using TJLB over other methods when considering liver biopsy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Referral for Liver Transplantation (LT)</strong></summary>
            <div>
                <ul><li>LT is a lifesaving procedure for some patients w/ ALF.</li><li>Relies on graft availability, significant resources, morbidity/mortality, lifelong immunosuppression.</li><li>Approximately half of ALF patients undergo LT; 1-year survival rates: 79% (Europe), 84% (US).</li></ul>
                
        <details>
            <summary><strong>Prognostic Scoring Systems</strong></summary>
            <div>
                <ul><li>King&#x27;s College Criteria (KCC) &amp; Model for End-Stage Liver Disease (MELD) are most studied.</li><li>KCC more accurately predicts hospital mortality in APAP-associated ALF.</li><li>MELD scores more accurately predict mortality in non-APAP-associated ALF.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>System-Specific Management</strong></summary>
            <div>
                <ul><li>ALF affects virtually every organ system, requiring targeted management strategies.</li></ul>
                
        <details>
            <summary><strong>Central Nervous System (CNS)</strong></summary>
            <div>
                <ul><li>Neurological manifestations range from hyperammonemia to HE &amp; ultimately cerebral edema (CE) w/ increased intracranial pressure (ICP).</li><li>Progression to grade 2 encephalopathy necessitates ICU monitoring.</li><li>Advanced grade 3–4 HE → endotracheal intubation for airway protection.</li></ul>
                
        <details>
            <summary><strong>Hyperammonemia Management</strong></summary>
            <div>
                <ul><li>Continuous renal replacement therapy (CRRT) effectively ↓ ammonia levels.</li><li>↓ serum ammonia w/ CRRT → ↓ mortality &amp; ↑ transplant-free survival (TFS) @ 21 days.</li><li>↓ intracranial hypertension (ICH) &amp; CE associated w/ ↑ CRRT use in APAP-induced ALF.</li><li>Ornithine phenylacetate: failed to show improvement in RCT for cirrhosis, thus not endorsed for ALF.</li></ul>
                
        <details>
            <summary><strong>Recommendation: CRRT for Hyperammonemia</strong></summary>
            <div>
                <ul><li>In patients w/ ALF &amp; grade 2 or higher encephalopathy, suggest early CRRT for hyperammonemia management, even w/o conventional RRT indications.</li><li>GRADE: conditional, very low quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hepatic Encephalopathy (HE) Treatment</strong></summary>
            <div>
                <ul><li>Lactulose: first-line for HE in chronic liver disease; adopted orally for ALF patients alert enough to maintain airway (grade 1–2).</li><li>Discontinue lactulose in advanced grade 3–4 HE.</li><li>Rifaximin: effective w/ lactulose in chronic liver disease; adopted by many transplant centers for ALF, but data lacking.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cerebral Edema (CE) &amp; Increased Intracranial Pressure (ICP)</strong></summary>
            <div>
                <ul><li>Overall incidence of ↑ ICP ↓ in ALF, but mortality remains high when present.</li><li>First-line treatment: hyperosmolar therapy (mannitol, hypertonic saline), hyperventilation, CRRT.</li><li>Avoid hyponatremia; target serum sodium 145–150 mmol/L (no supporting literature for this specific range).</li><li>Correction rate: not exceeding 6–8 mmol/L in 24 hours.</li><li>Hypertonic saline (3%): bolus 250–500 mL or continuous infusion to maintain serum sodium &lt;160 mmol/L.</li></ul>
                
        <details>
            <summary><strong>ICP Monitoring</strong></summary>
            <div>
                <ul><li>Utility questioned due to ↑ CRRT use &amp; ↓ ICH rates.</li><li>No survival advantage for ICP monitoring in recent reviews; favor general ICP-lowering strategies.</li><li>May be considered in centers w/ expertise &amp; highly selected patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Therapeutic Hypothermia</strong></summary>
            <div>
                <ul><li>Studies heterogeneous; intervention did not improve overall patient survival despite efficiency &amp; low bleeding risk.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concepts: CNS Management</strong></summary>
            <div>
                <ul><li>Patients w/ ALF w/ grade 2 or higher encephalopathy should be monitored in an ICU setting.</li><li>Patients w/ ALF w/ grade 3 &amp; 4 encephalopathy should be intubated for airway protection.</li><li>No conclusive evidence to recommend for/against lactulose or rifaximin for HE in ALF.</li><li>No conclusive evidence to recommend routine ICP monitor placement in ALF.</li><li>No conclusive evidence to recommend routine use of hypothermia to control ICP in ALF.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Coagulopathy</strong></summary>
            <div>
                <ul><li>Complex mechanism, incompletely understood; multiple factors contribute to hemostasis changes.</li><li>INR is not an accurate predictor of bleeding risk in ALF despite frequent extreme elevation.</li><li>Evidence suggests a rebalanced state of hemostasis.</li><li>Clinically significant bleeding uncommon (≈5% of deaths).</li></ul>
                
        <details>
            <summary><strong>Misinterpretation of INR</strong></summary>
            <div>
                <ul><li>Elevated INR often misinterpreted as ↑ hemorrhagic tendency → improper prophylactic transfusion.</li><li>Routine use of FFP, cryoprecipitate, platelets, or other correction may ↑ risk of death or need for LT due to transfusion reaction, thrombosis, transfusion-related acute lung injury.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Viscoelastic Testing (VET)</strong></summary>
            <div>
                <ul><li>May allow more global assessment of procoagulant/anticoagulant pathways, hyperfibrinolysis, platelet function, clot formation.</li><li>62% of ALI/ALF patients had normal mean rotational thromboelastography parameters despite mean INR of 3.4 ± 1.7.</li><li>Associated w/ disease severity, but less clear association w/ bleeding events.</li><li>Limitation: lacks ability to assess protein C &amp; von Willebrand factor activity.</li><li>Society of Critical Care Medicine recommends VET over INR for bleeding/thrombosis risk in critically ill ALF patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Correction for Invasive Procedures</strong></summary>
            <div>
                <ul><li>May be necessary before high-risk procedures (e.g., ICP monitoring) due to intracranial hemorrhage risk.</li><li>FFP &amp; platelet transfusions have volume overload risk; Factor VII used in these settings.</li><li>ICP monitors can be placed safely when clinical protocol followed, including aggressive coagulopathy correction.</li></ul>
                
        <details>
            <summary><strong>Key Concepts: Coagulopathy</strong></summary>
            <div>
                <ul><li>INR does not accurately reflect bleeding risk in ALF patients.</li><li>Viscoelastic tests may provide a more accurate assessment of coagulopathy in ALF patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation: Routine Coagulopathy Correction</strong></summary>
            <div>
                <ul><li>In patients w/ ALF, in absence of active bleeding or impending high-risk procedure, recommend against routine correction of coagulopathy.</li><li>GRADE: conditional, very low quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Infection</strong></summary>
            <div>
                <ul><li>High incidence of bacterial infections in ALF, associated w/ high mortality.</li><li>Fungal infections account for up to 32% of infections.</li><li>Prophylactic antimicrobials: not supported by data; did not ↓ bloodstream infection rate or 21-day mortality.</li></ul>
                
        <details>
            <summary><strong>Early Detection &amp; Biomarkers</strong></summary>
            <div>
                <ul><li>Usual indicators (leukocytosis, fever) absent in up to 30% of infected ALF cases.</li><li>Procalcitonin: elevated in both infected &amp; uninfected ALF/chronic liver disease patients; poor indicator of infection, seems to indicate inflammation.</li><li>Regular surveillance of blood, urine, sputum cultures recommended.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Empiric Therapy</strong></summary>
            <div>
                <ul><li>Empiric antibiotic &amp; antifungal therapies may be considered w/ clinical deterioration.</li><li>If antimicrobial prophylaxis undertaken, consider local microbial resistance patterns.</li></ul>
                
        <details>
            <summary><strong>Key Concepts: Infection</strong></summary>
            <div>
                <ul><li>Early assessment for infection is prudent because clinical signs are frequently absent.</li><li>Insufficient evidence to recommend procalcitonin as infection biomarker.</li><li>Empiric antibiotic &amp; antifungal therapies may be considered w/ clinical deterioration.</li><li>Suggest regular surveillance cultures; optimal frequency unknown.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation: Prophylactic Antimicrobials</strong></summary>
            <div>
                <ul><li>In patients w/ ALF, recommend against routine use of prophylactic antimicrobial agents, given no improvement in bloodstream infection rate or 21-day mortality.</li><li>GRADE: conditional, low quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hemodynamics and Renal Failure</strong></summary>
            <div>
                <ul><li>Hemodynamic profile resembles septic shock: hyperdynamic circulation, high cardiac output, low systemic vascular resistance, ↓ effective circulating volume.</li><li>Acute kidney injury (AKI) common (up to 70% of US ALFSG patients; 30% required RRT).</li></ul>
                
        <details>
            <summary><strong>Hemodynamic Management</strong></summary>
            <div>
                <ul><li>IV fluid resuscitation: primary intervention to maintain adequate tissue perfusion.</li><li>Pulse pressure variation measurements: proposed to assess fluid responsiveness &amp; guide vasopressor need (requires local expertise, further validation needed).</li><li>Vasopressor use: if IV fluids ineffective, to maintain satisfactory mean arterial pressure (MAP).</li><li>Target MAP: maintain cerebral perfusion pressure of 60–80 mm Hg.</li><li>Norepinephrine: preferred vasopressor → survival benefit &amp; ↓ adverse outcomes.</li><li>Vasopressin: may be added to potentiate norepinephrine effects.</li></ul>
                
        <details>
            <summary><strong>Recommendations: Hemodynamics</strong></summary>
            <div>
                <ul><li>In patients w/ ALF, recommend norepinephrine as first-line vasopressor for hypotension refractory to fluid resuscitation.</li><li>GRADE: strong, moderate quality of evidence.</li><li>In patients w/ ALF w/ hypotension not responsive to norepinephrine, suggest adding vasopressin as a secondary agent.</li><li>GRADE: conditional, low quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Acute Kidney Injury (AKI)</strong></summary>
            <div>
                <ul><li>Pathogenesis multifactorial: direct nephrotoxicity, sepsis, hemodynamic instability.</li><li>Increased severity of renal dysfunction associated w/ ↑ mortality.</li><li>Most patients w/ AKI in US ALFSG cohort did not require ongoing renal support after ALF resolution.</li></ul>
                
        <details>
            <summary><strong>Renal Replacement Therapy (RRT)</strong></summary>
            <div>
                <ul><li>Indications: acid-base disturbances, oliguria, volume overload.</li><li>CRRT: preferred modality → ↓ risk of cardiovascular instability &amp; CE vs. intermittent hemodialysis.</li><li>CRRT effectively ↓ ammonia level; hyperammonemia is an increasing indication for RRT independent of AKI.</li><li>Early CRRT for hyperammonemia improves survival by preventing severe complications.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concepts: Hemodynamics &amp; Renal Failure</strong></summary>
            <div>
                <ul><li>In patients w/ ALF &amp; hypotension, IV fluid resuscitation should be initiated.</li><li>RRT should be considered early in patients w/ AKI, electrolyte/metabolic abnormalities, and/or volume overload.</li><li>In patients w/ ALF requiring RRT, recommend CRRT over intermittent hemodialysis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Nutritional and Metabolic Support</strong></summary>
            <div>
                <ul><li>Severe loss of hepatocellular function → abnormal carbohydrate, protein, lipid metabolism.</li><li>Energy expenditure ↑ by 18%–30% vs. healthy controls.</li><li>Nutritional support recommended if oral intake not expected within 5–7 days.</li><li>Oral nutrition for mild mental status alterations; otherwise, enteral support preferred.</li></ul>
                
        <details>
            <summary><strong>Protein Intake</strong></summary>
            <div>
                <ul><li>Increased protein intake not shown to worsen encephalopathy in cirrhosis; 1.0–1.5 gm/kg daily recommended.</li><li>Concern w/ severe hyperammonemia (&gt;150 μMol/L) &amp; HE in ALF.</li><li>Consider delayed supplementation for first 24–48 hours, then restart at lower range (1.0 gm/kg) w/ close ammonia monitoring.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Glucose, Fluid, and Electrolyte Support</strong></summary>
            <div>
                <ul><li>More urgent concern due to short ALF duration.</li><li>Hypoglycemia: frequent manifestation → ↓ hepatic glycogen, impaired gluconeogenesis, insulin resistance.</li><li>Hypoglycemia contributes to encephalopathy &amp; associated w/ ↑ mortality.</li><li>Monitor mental status every 1–2 hours.</li><li>Dextrose 10% solution: constant infusion to maintain blood sugar 150–180 mg/dL.</li><li>Avoid hypotonic solutions → hyponatremia risk &amp; CE worsening.</li><li>Magnesium &amp; phosphorus: monitor every 8–12 hours, replenish as needed.</li></ul>
                
        <details>
            <summary><strong>Key Concepts: Nutritional &amp; Metabolic Support</strong></summary>
            <div>
                <ul><li>In patients w/ ALF, monitoring &amp; correction of glucose, fluid, &amp; electrolyte imbalances should be performed.</li><li>In patients w/ ALF, enteral nutritional support should be started if patient unable to resume oral intake within 5–7 days.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Other Management Considerations</strong></summary>
            <div>
                <ul><li>Exploration of advanced therapies for liver support.</li></ul>
                
        <details>
            <summary><strong>High-Volume Plasma Exchange (HVPE)</strong></summary>
            <div>
                <ul><li>Plasmapheresis of 8–12 L or 15% of ideal body weight w/ FFP.</li><li>Associated w/ improved transplant-free survival.</li><li>Retrospective review (32 ALF patients): overall survival 94% (treated) vs 69% (untreated).</li><li>HVPE improved coagulopathy, bilirubin, ammonia levels.</li><li>Concern regarding applicability across varying ALF etiologies.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Artificial Liver Support Systems</strong></summary>
            <div>
                <ul><li>Great interest as bridge to transplant or liver recovery.</li><li>Two types: artificial &amp; bioartificial.</li><li>None received US FDA marketing approval; available for investigational/compassionate use.</li><li>Examples: Molecular Adsorbent Recirculating System, Single-Pass Albumin Dialysis, Fractionated Plasma Separation and Adsorption system (FPSA).</li><li>Efficacy data: lack of evidence to support any particular system.</li><li>Only RCT (102 patients): improved 6-month survival only in APAP-induced ALF group.</li></ul>
                
        <details>
            <summary><strong>Key Concept: HVPE &amp; Artificial Liver Support</strong></summary>
            <div>
                <ul><li>Insufficient evidence to recommend for/against routine use of HVPE or artificial/bioartificial liver support devices in ALF patients.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Etiology-Specific Management</strong></summary>
            <div>
                <ul><li>Time-sensitive, etiology-specific interventions are crucial in addition to general management.</li></ul>
                
        <details>
            <summary><strong>Drug-Induced Liver Injury (DILI)</strong></summary>
            <div>
                <ul><li>Leading cause of ALF in US &amp; many Western countries.</li></ul>
                
        <details>
            <summary><strong>Acetaminophen Hepatotoxicity (APAP)</strong></summary>
            <div>
                <ul><li>Leading cause of DILI &amp; ALF in US.</li><li>Occurs dose-dependently: single intentional overdose (&gt;10–15g) or unintentional (&gt;10g over days).</li><li>Fasting/alcohol ingestion may contribute to toxicity even at recommended dosages.</li><li>Mechanism: high doses overwhelm sulfation/glucuronidation → shunted to cytochrome P450 pathways → toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI) formation → oxidative hepatocyte injury &amp; necrosis.</li><li>APAP levels may be undetectable @ presentation; NAPQI-protein adducts may aid identification.</li><li>Presentation: asymptomatic or nonspecific constitutional symptoms initially; rapid progression to liver failure within 72–96 hours.</li><li>Labs: predominantly hepatocellular pattern, marked transaminase elevations (&gt;3,000 U/L), coagulopathy, relatively mild hyperbilirubinemia.</li><li>Prognosis: most recover w/ aggressive medical management, esp. w/ early identification/treatment.</li><li>Mortality rate ≈28%; up to 1/3 require LT.</li></ul>
                
        <details>
            <summary><strong>Management of APAP Hepatotoxicity</strong></summary>
            <div>
                <ul><li>Immediate intervention for suspected toxicity.</li><li>Gastric decontamination: 1–2 g/kg single-dose activated charcoal effective if administered within 4 hours post-ingestion; data support administration after 4 hours, esp. w/ NAC.</li><li>N-acetylcysteine (NAC): only effective antidote; IV preferred route (ease of use, tolerability).</li><li>Continue NAC beyond initial protocol for persistent coagulopathy (INR &gt;1.5) &amp; encephalopathy.</li><li>Begin NAC as soon as toxicity suspected, even if ingestion time unknown (proven benefit of late administration).</li><li>Rumack-Matthew nomogram: guides administration for single time point ingestions.</li><li>End point: INR &lt;1.5, ALT &lt;50% of peak (or 3 consecutive values &lt;1,000 IU/L), and/or undetectable APAP level.</li><li>Novel therapies: 4-Methylpyrazole (NAPQI inhibition), Calmangafodipir (early safety/tolerability w/ NAC, but mechanism/benefits lacking).</li></ul>
                
        <details>
            <summary><strong>Key Concepts: APAP Hepatotoxicity</strong></summary>
            <div>
                <ul><li>Duration of NAC treatment should be individualized based on clinical condition &amp; lab values.</li><li>For APAP overdose, recommend single-dose activated charcoal if ingestion known within 4 hours.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation: Early NAC for APAP Toxicity</strong></summary>
            <div>
                <ul><li>In patients w/ suspected APAP toxicity, recommend early administration of NAC.</li><li>GRADE: strong, low quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Nonacetaminophen Drug Hepatotoxicity (I-DILI)</strong></summary>
            <div>
                <ul><li>Second leading cause of ALF after APAP in US &amp; Western countries.</li><li>Not dose-dependent; variable latency period.</li><li>Most commonly implicated: antimicrobials (antituberculosis, sulfa, nitrofurantoin, terbinafine, azole antifungals).</li><li>Second most common: Complementary &amp; Alternative Medications (CAM) → 8-fold ↑ in CAM-associated ALF over 25 years (2.9% to 24.1% of I-DILI ALF cases).</li><li>Demographics: most I-DILI patients are women (66%–71%).</li><li>Presentation: historically advanced coma grade ≥2 (68%); newer data show most (66.4%) w/ lower-grade encephalopathy.</li><li>Labs: deep jaundice (bilirubin &gt;15 mg/dL), predominantly hepatocellular injury (aminotransferases generally &lt;1,000 IU/L).</li><li>Prognosis: favorable generally, but ALF progression has dismal TFS (23.5%–38.7% @ 3 weeks); overall survival 66%.</li><li>CAM-induced ALF: more severe than prescription DILI → significantly higher LT rates (61% vs 36%, P &lt; 0.005) &amp; lower 21-day TFS (17% vs 34%, P = 0.044).</li><li>Resources: NIH-funded database www.LiverTox.nih.gov for DILI evaluation.</li></ul>
                
        <details>
            <summary><strong>Management of Non-APAP Drug Hepatotoxicity</strong></summary>
            <div>
                <ul><li>Discontinue suspect drug immediately.</li><li>Supportive care is primary.</li><li>IV NAC: improved TFS in non-APAP ALF w/ early coma grade (I-II) → 52% (treatment) vs 30% (placebo).</li><li>Meta-analysis: overall survival, posttransplant survival, TFS better in NAC-treated group (5% of patients had DILI).</li><li>Corticosteroid therapy: may be effective for hypersensitivity or autoimmune features (e.g., minocycline, nitrofurantoin).</li><li>Less certain efficacy w/o immune-related features; studies small/heterogeneous.</li><li>Immune checkpoint inhibitor hepatitis: cessation crucial; corticosteroid therapy for persistent grade 2 or any grade 3/4 aminotransferase/bilirubin elevation.</li><li>ALF rarely described; LT may not be viable due to underlying malignancy/hyperacute rejection risk.</li></ul>
                
        <details>
            <summary><strong>Recommendation: IV NAC for Non-APAP ALF</strong></summary>
            <div>
                <ul><li>In patients w/ non-APAP ALF, suggest initiation of IV NAC.</li><li>GRADE: strong, moderate quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</strong></summary>
            <div>
                <ul><li>Rare, severe drug-induced systemic illness.</li><li>Characterized by extensive skin rash, fever, eosinophilia, atypical lymphocytosis, multiorgan dysfunction.</li><li>Presentation: typically 2–8 weeks after exposure.</li><li>Hepatotoxicity: most commonly cholestasis (37%) or cholestatic hepatitis (27%).</li><li>May progress to ALF: 7 of 16 patients developed ALF, 2 died, 5 underwent LT.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Viral Hepatitis</strong></summary>
            <div>
                <ul><li>Worldwide, AVH is leading cause of ALF.</li><li>In US ALFSG, AVH accounts for 12% of ALF cases (Hepatitis A: 3%, B: 7%, E: 2%).</li><li>Japan: 40% of ALF due to HBV; India/Bangladesh: nearly half due to acute HEV.</li><li>Acute HCV generally not associated w/ ALF.</li><li>Rare causes: HSV, zoster, CMV, EBV, adenovirus (often in immunocompromised).</li><li>AVH-induced ALF suspected to be underrecognized; substantial proportion of indeterminate cases may be viral.</li><li>Presentation: acute-to-subacute w/ viral prodrome (fevers, chills, nausea, vomiting, diarrhea, malaise, body aches, flu-like illness) preceding ALF signs/symptoms.</li><li>Labs: predominantly hepatocellular pattern, markedly elevated transaminase levels.</li><li>Prognosis: poor spontaneous survival (25%) for AVH; manage in transplant center.</li></ul>
                
        <details>
            <summary><strong>Hepatitis A (HAV)</strong></summary>
            <div>
                <ul><li>Favorable prognosis generally; &lt;1% of adults progress to ALF.</li><li>HAV ALF: transplant-free survival only 70%.</li><li>Prognostic model (day 1): ALT &lt;2,600 IU/L, creatinine &gt;2.0 mg/dL, intubation, pressor use → ≥2 factors predict worse outcomes (LT/death) w/ 92% sensitivity, 88% specificity.</li><li>25% of patients showed negative PCR, correlating w/ significantly worse outcomes (lower spontaneous survival).</li><li>Vaccination available for postexposure prophylaxis.</li></ul>
                
        <details>
            <summary><strong>Management of HAV</strong></summary>
            <div>
                <ul><li>Largely supportive; no specific antiviral agent proven effective.</li><li>Early LT associated w/ good outcomes when needed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hepatitis B (HBV)</strong></summary>
            <div>
                <ul><li>Causes ALF in ≈1% of infected patients; incidence may be underestimated (HBV DNA &amp; HBsAg undetectable @ presentation).</li><li>US: de novo infection &amp; reactivation of latent infection (immunocompromised) are significant causes.</li><li>Unfavorable prognosis: up to 75% require LT or die.</li><li>Major risk factor: coinfection/superinfection w/ hepatitis D virus (HDV) → up to 20% of HBV-HDV acute coinfection &amp; 5% of HDV superinfection result in fulminant ALF (up to 80% mortality w/o transplant).</li><li>Vaccination safe, effective, widely available.</li></ul>
                
        <details>
            <summary><strong>Management of HBV and HDV</strong></summary>
            <div>
                <ul><li>Distinguishing primary vs. exacerbation of chronic infection can be difficult.</li><li>Antiviral therapy in acute HBV-ALF: controversial.</li><li>Less relevant in primary infections (VL already low, immune-mediated injury).</li><li>Earlier studies: clear benefit of lamivudine in fulminant HBV, esp. if initiated early.</li><li>Later study: no difference in outcomes between nucleoside(tide) analog-treated vs. untreated.</li><li>Antiviral therapy justifiable in severe hepatitis due to HBV reactivation (high VL).</li><li>Early lamivudine/entecavir for severe reactivation HBV: significantly ↓ VL; tenofovir showed improved survival.</li><li>No data for tenofovir alafenamide.</li><li>HDV superinfection: no effective therapy beyond HBV antiviral therapy (interferon contraindicated in ALF).</li><li>Myrcludex B (bulevirtide) shows early promise but not evaluated in ALF.</li><li>Lonarfarnib (prenylation inhibitor) in phase 3 trials for non-ALF patients.</li></ul>
                
        <details>
            <summary><strong>Recommendation: Antiviral for HBV Reactivation</strong></summary>
            <div>
                <ul><li>In patients w/ ALF due to reactivation of HBV, recommend starting antiviral therapy w/ entecavir-based or tenofovir-based regimen.</li><li>GRADE: strong, low quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Hepatitis E (HEV)</strong></summary>
            <div>
                <ul><li>Accounts for up to 40% of ALF in developing countries; grossly underrecognized in Western countries.</li><li>US/Germany studies: up to 1/5 to 1/2 of DILI-attributed ALF cases were HEV.</li><li>Most cases: pregnancy or immunocompromised patients.</li><li>Pregnant women: highest mortality risk (up to 25%).</li><li>Disseminated intravascular coagulation: distinctive feature of HEV-ALF during pregnancy.</li><li>Severity of HEV infection &amp; VL in mother predicts vertically transmitted infection in fetus.</li><li>HEV recombinant vaccine approved in China (2012); no US FDA-approved vaccine.</li></ul>
                
        <details>
            <summary><strong>Management of HEV</strong></summary>
            <div>
                <ul><li>Most cases self-limited; usually supportive care only.</li><li>Some evidence for chronic HEV treatment w/ pegylated interferon or ribavirin, but no proven benefit in ALF.</li><li>LT remains only treatment option in HEV-ALF.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Rare Viral Infections</strong></summary>
            <div>
                <ul><li>Case reports/series of ALF attributed to HSV, zoster, CMV, EBV, adenovirus.</li><li>Most often implicated in immunocompromised individuals.</li><li>Not always clear if reactivation of latent viruses (EBV, CMV) is primary insult or systemic disease consequence.</li><li>Herpes viruses: skin manifestations not always apparent.</li></ul>
                
        <details>
            <summary><strong>Hepatitis C (HCV)</strong></summary>
            <div>
                <ul><li>Can cause severe hepatitis, but no definitive evidence for ALF.</li><li>Current antiviral therapies → &gt;95% cure rate.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Rare Viral Infections</strong></summary>
            <div>
                <ul><li>Herpes Simplex Virus (HSV): Early IV acyclovir indicated if suspected (best chance for good outcome); do not wait for serology.</li><li>HSV-induced ALF carries poor prognosis despite rapid antiviral treatment.</li><li>Viral resistance to acyclovir low, but up to 10% in immunocompromised → IV foscarnet alternative.</li><li>Risk factors for death/LTx: male, older, immunocompromised, ALT &gt;5,000 IU/L, platelets &lt;75 × 103/L, coagulopathy, encephalopathy.</li><li>LT is rescue therapy; lifelong antiviral suppressive therapy indicated due to recurrence risk.</li><li>Varicella Zoster Virus: Rare cause of ALF; suspect w/ characteristic rash.</li><li>Prompt treatment w/ IV acyclovir.</li><li>Cytomegalovirus (CMV): Rarely implicated in immunosuppression.</li><li>IV ganciclovir recommended for CMV hepatitis.</li><li>Epstein-Barr Virus (EBV): Primary infection seen in &lt;1% of ALF cases; high case fatality rate.</li><li>Treatment: acyclovir or ganciclovir.</li></ul>
                
        <details>
            <summary><strong>Key Concept: HSV/Zoster Empiric Treatment</strong></summary>
            <div>
                <ul><li>In patients w/ ALF, grade 2 encephalopathy, &amp; features suggestive of HSV or zoster infection, suggest empiric treatment w/ IV acyclovir until confirmatory viral PCRobtained.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Mushroom Poisoning</strong></summary>
            <div>
                <ul><li>Hepatotoxicity after ingestion of amatoxin-containing mushrooms (Amanita sp., Galerina sp., Lepiota sp.).</li><li>≈50 lethal exposures annually in US, mostly Amanita species.</li><li>Amanitin: heat stable, water insoluble; 1-2 medium caps lethal dose.</li><li>Toxins concentrated in hepatocytes → apoptosis.</li><li>Patients progress through 3 distinct clinical phases after ingestion.</li></ul>
                
        <details>
            <summary><strong>Clinical Phases</strong></summary>
            <div>
                <ul><li>6–12 hours: Gastroenteritis (vomiting, diarrhea, abdominal pain, dehydration).</li><li>24–36 hours: Quiescent period (clinical symptom improvement, but evolving hepatotoxicity labs).</li><li>4–7 days: Onset of progressive liver &amp; multiorgan failure (coagulopathy, acidosis, encephalopathy, seizures, renal failure).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnosis &amp; Prognosis</strong></summary>
            <div>
                <ul><li>Confirmatory tests not available; exclude mushroom ingestion in all ALF patients.</li><li>Previously high death risk w/o LT; recent data: most (23/27) survive w/o transplantation.</li><li>Favorable prognosis predictors: peak AST &lt;4,000 IU/mL, peak INR &lt;2, serum factor V &gt;30%.</li><li>Mushroom-specific prognostic criteria (Escudie criteria) can predict 28-day mortality w/ 100% accuracy, identifying fatal cases earlier than KCC.</li><li>LT evaluation can be initiated before HE development based on Escudie criteria.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Management of Mushroom Toxicity</strong></summary>
            <div>
                <ul><li>Contact poison control center for guidance.</li><li>Gastric lavage: recommended within 1 hour of toxin ingestion to prevent absorption (may not be possible due to lag time).</li><li>Contraindications to lavage: recent surgery, GI hemorrhage, altered mental status.</li><li>Activated charcoal: recommended soon after ingestion to disrupt enterohepatic circulation of amatoxin.</li><li>Doses: 50g every 4 hours or 25g every 2 hours; reduced to 12.5g every hour for tolerability.</li><li>IV hydration: maintain urinary output 100–200 mL/hr for 4–5 days to eliminate toxins (60%–80% amatoxins filtered by kidneys in first few hours).</li><li>IV silibinin dihemisuccinate: sufficient evidence to support use in acute Amanita phalloides poisoning.</li><li>Dosing: 20–50 mg/kg/d for 48–96 hours, or 5 mg/kg over 1 hour then 20 mg/kg/d for 6 days or until transaminases normalize.</li><li>Mechanism: α-amanitin membrane transport inhibitor &amp; free radical scavenger.</li><li>US ALFSG data: only 23% received silibinin (not US FDA approved).</li><li>IV penicillin G: believed to block hepatic uptake of α-amanitin; second-line therapy (inferior to silibinin).</li><li>Dosing: continuous infusion 1,000,000 IU/kg day 1, then 1,500,000 IU/kg days 2 &amp; 3.</li><li>IV NAC: beneficial in Amanita phalloides poisoning.</li><li>Dosing: 150 mg/kg over 15 min, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (or similar to APAP toxicity).</li><li>Hemodialysis, hemoperfusion, plasmapheresis: little benefit due to rapid absorption/excretion of amatoxin.</li><li>Molecular Adsorbent Recirculating System: some evidence of benefit, but more data needed.</li><li>LT: effective intervention for ALF due to Amanita phalloides poisoning w/ excellent outcomes.</li></ul>
                
        <details>
            <summary><strong>Key Concepts: Mushroom Poisoning</strong></summary>
            <div>
                <ul><li>Escudie criteria can predict need for LT even before HE development.</li><li>Gastric lavage &amp; activated charcoal should be administered within first few hours after ingestion, provided no contraindications.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation: IV Silibinin for Mushroom Poisoning</strong></summary>
            <div>
                <ul><li>In patients w/ ALF due to mushroom poisoning, recommend initiation of IV silibinin ASAP.</li><li>IV penicillin G may be used if IV silibinin unavailable.</li><li>GRADE: conditional, very low quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Wilson Disease (WD)</strong></summary>
            <div>
                <ul><li>Can manifest from asymptomatic liver enzyme abnormalities to acute decompensated disease.</li><li>Most patients 5–35 years old; women more likely to present w/ ALF (2:1 female:male).</li><li>ALF can occur in known WD patients discontinuing or poorly adhering to copper-chelating therapy.</li><li>Labs: Coombs-negative hemolytic anemia (acute intravascular hemolysis), rapid progression to renal failure, modest transaminase elevation, normal/very low alkaline phosphatase (&lt;40 IU/L).</li><li>Serum copper: may be markedly elevated due to sudden release from injured liver tissue.</li><li>Low ceruloplasmin: common in ALF from other etiologies too.</li><li>Liver biopsy: rarely needed; if performed, often shows underlying advanced fibrosis/cirrhosis.</li><li>Diagnosis: quantitative copper measurement of liver tissue or genetic testing (should not delay LT consideration).</li><li>Prognosis: guarded w/o LT; medical therapy alone rarely successful.</li></ul>
                
        <details>
            <summary><strong>Management of Acute Decompensated WD</strong></summary>
            <div>
                <ul><li>Copper depletion: plasmapheresis, albumin dialysis, plasma exchange, continuous hemofiltration (temporizing measures to avoid renal injury).</li><li>Copper chelators (D-penicillamine, trientine): ineffective in acute decompensated WD.</li><li>Prognostic criteria: WD prognostic index, revised King&#x27;s College score of WD prognostic index.</li><li>LT: excellent outcomes; 1-year &amp; 5-year patient survival 90.1% &amp; 89% (children), 88.3% &amp; 86% (adults).</li></ul>
                
        <details>
            <summary><strong>Key Concept: LT Evaluation for WD</strong></summary>
            <div>
                <ul><li>In patients w/ ALF due to suspected/confirmed WD, LT evaluation should be initiated during diagnosis due to lack of effective medical therapy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Autoimmune Hepatitis (AIH)</strong></summary>
            <div>
                <ul><li>Acute severe AIH (AS-AIH): jaundice, no cirrhosis, INR ≥1.5, symptom onset &lt;26 weeks.</li><li>Progresses to ALF in up to 3%–6% of patients.</li><li>Black patients w/ AIH: higher risk of ALF requiring LT vs. White patients.</li><li>HLA types DR3 &amp; DR7: more common w/ type 2 AIH, associated w/ more severe disease.</li><li>Diagnosis: difficult due to overlap w/ exacerbation of chronic AIH or immune-mediated DILI.</li><li>Presentation: typically subacute; hepatocellular injury pattern.</li><li>Serology: elevated ANA, ASMA, IgG.</li><li>Liver biopsy: may show nonspecific findings; distinguishing features: centrilobular zone injury, prominent lymphoplasmacytic lobular inflammation, centrilobular confluent necrosis w/o significant portal inflammation.</li><li>US ALFSG: 2 specific patterns of massive hepatic necrosis (centrilobular hemorrhagic necrosis or confluent necrosis superimposed on chronic hepatitis) more specific for autoimmune etiology.</li><li>Plasma cell infiltrate: characteristic of AIH.</li><li>AS-AIH likely underrecognized → delayed treatment.</li><li>Prognosis: significantly improved w/ corticosteroid therapy &amp; LT.</li><li>Pretransplant era survival &lt;20%; recent series mortality 16%–19%; prognosis associated w/ initial disease severity.</li></ul>
                
        <details>
            <summary><strong>Management of AIH</strong></summary>
            <div>
                <ul><li>Corticosteroid therapy: well-established for chronic AIH.</li><li>AS-AIH w/o ALF: glucocorticoid therapy (prednisone/prednisolone 0.5–1 mg/kg or 60 mg daily) beneficial w/o ↑ infection risk.</li><li>Therapy should not delay LT evaluation.</li><li>Up to 48% of treated patients likely to require LT.</li><li>SURFASA score (INR + bilirubin): highly predictive (88% specificity, 84% sensitivity) of LT or death in AS-AIH w/o ALF.</li><li>Identifies nonresponders within 3 days of corticosteroids for LT referral.</li><li>Corticosteroid therapy in chronic AIH exacerbation or ALF: mixed data (improved outcome/TFS vs. no benefit).</li><li>More recent data: in select patients, corticosteroids may improve outcome &amp; TFS in AIH-ALF.</li><li>Vigilant surveillance for infection.</li><li>Budesonide &amp; other immunosuppressants (tacrolimus): not well supported for severe acute AIH; patients should be immediately evaluated for LT.</li></ul>
                
        <details>
            <summary><strong>Key Concepts: AIH Management</strong></summary>
            <div>
                <ul><li>In patients w/ AS-AIH, recommend use of IV corticosteroids.</li><li>In patients w/ AS-AIH that has progressed to ALF, recommend early evaluation for LT.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pregnancy-Related Acute Liver Failure</strong></summary>
            <div>
                <ul><li>Rare (2.2% of &gt;3,100 patients in US ALFSG).</li><li>Pregnancy-specific causes: HELLP syndrome &amp; acute fatty liver of pregnancy (AFLP).</li><li>Present during third trimester or immediate postpartum period.</li><li>Difficult to distinguish HELLP &amp; AFLP due to overlapping features.</li><li>HELLP &amp; AFLP each accounted for 25% of cases; remaining half due to nonpregnancy-specific causes (APAP, HSV, AIH, DILI, cancers, Kikuchi-Fujimoto, thyrotoxicosis).</li><li>Median gestational age @ presentation: higher in HELLP/AFLP (36 weeks) vs. nonpregnancy-specific ALF (30 weeks).</li><li>2/3 of HELLP/AFLP patients experienced preeclampsia/eclampsia; ≈90% required emergency cesarean delivery.</li><li>Outcomes: 69% spontaneous recovery, 14% survived after LT, 11% died @ 21 days.</li><li>Predictors of worse survival in HELLP/AFLP ALF: HE, elevated lactate, higher MELD score.</li></ul>
                
        <details>
            <summary><strong>Management of Pregnancy-Related ALF</strong></summary>
            <div>
                <ul><li>Obstetric emergency; multidisciplinary care.</li><li>Cornerstone: prompt delivery of fetus ASAP.</li><li>Supportive care for metabolic, renal, respiratory complications.</li><li>Clinical/laboratory abnormalities may persist for weeks post-delivery; careful decision for LT.</li><li>Swansea criteria: developed for AFLP diagnosis.</li><li>Increased Swansea score, HE, platelet-to-white blood cell ratio (PWR) may be helpful prognostic indicators.</li><li>LT for AFLP: good survival outcomes comparable to other etiologies.</li><li>Hepatic bleeding, hematoma, rupture: may occur (esp. HELLP); may require urgent surgical intervention.</li></ul>
                
        <details>
            <summary><strong>Key Concepts: Pregnancy-Related ALF</strong></summary>
            <div>
                <ul><li>Supportive care &amp; multidisciplinary management essential; prompt delivery of fetus crucial.</li><li>In patients w/ pregnancy-associated ALF who fail to improve after delivery, suggest prompt evaluation for LT.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Budd-Chiari Syndrome (BCS)</strong></summary>
            <div>
                <ul><li>Rarest cause of ALF; most often White women in 4th–5th decades.</li><li>Characterized by obstruction of hepatic venous outflow tract (venous thrombosis).</li><li>Underlying hypercoagulable states: pregnancy, oral contraceptive use, polycythemia vera, membranous webs.</li><li>Complete occlusion of hepatic veins → ALF via severe ischemia &amp; massive hepatocyte necrosis.</li><li>Presentation: acute-to-subacute illness w/ abdominal pain &amp; ascites.</li><li>Labs: predominantly hepatocellular liver injury, marked aminotransferase elevation (AST &gt; ALT in 1000s).</li><li>Diagnosis: evaluate for underlying hypercoagulable disorder.</li><li>Prognosis: historically dismal TFS (37%–40%); ↑ to 80% in recent decades.</li></ul>
                
        <details>
            <summary><strong>Management of BCS</strong></summary>
            <div>
                <ul><li>Mainstay: initiate anticoagulation to halt thrombosis &amp; restore patency.</li><li>IV heparin: start promptly if no contraindications.</li><li>ALFSG review: 71% anticoagulated w/ heparin; overall survival 42%; anticoagulated patients more likely to survive, esp. w/ early initiation.</li><li>Other interventions: thrombolysis + angioplasty, TIPS, surgical shunting, LT.</li><li>Thrombolytic therapy: risk of bleeding, stroke, pulmonary embolism; reserved for select patients w/ recent clots.</li><li>Angioplasty: effective for membranous web obstruction.</li><li>Shunt creation: necessary for those failing medical therapy, angioplasty, or stenting.</li><li>TIPS or direct intrahepatic portocaval shunt preferred over transabdominal surgical shunts.</li><li>TIPS data increasing despite lack of RCTs; polytetrafluoroethylene stent preferred (↓ occlusion rate).</li><li>LT: timely listing for BCS-ALF patients not responding to medical/therapeutic intervention.</li><li>UNOS data: BCS status 1A patients had comparable posttransplant survival to non-status 1A (1-year: 82% vs 86%).</li><li>Large European study: 1-year, 3-year, 5-year posttransplant survival rates of 76%, 71%, 68%.</li></ul>
                
        <details>
            <summary><strong>Key Concepts: BCS Management</strong></summary>
            <div>
                <ul><li>In patients w/ BCS leading to ALF, TIPS is preferred intervention in those who fail anticoagulation.</li><li>In patients w/ BCS-induced ALF, recommend heparin as initial therapy, in absence of contraindications to anticoagulation.</li><li>In patients w/ BCS-induced ALF who do not respond to medical &amp; therapeutic interventions, recommend LT.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Secondary Causes of Acute Liver Failure</strong></summary>
            <div>
                <ul><li>Less common but important etiologies.</li></ul>
                
        <details>
            <summary><strong>Ischemic Liver Injury</strong></summary>
            <div>
                <ul><li>Also called &#x27;hypoxic hepatitis&#x27; or &#x27;shock liver&#x27;.</li><li>Results from transiently or persistently ↓ hepatic perfusion.</li><li>Often occurs w/ congestive heart failure, sepsis, traumatic injury, major surgery.</li><li>Documented hypotension not always identified.</li><li>Presentation: acute-to-subacute; severe hepatocellular injury (marked AST &gt;10,000 IU/L).</li><li>Labs: bilirubin typically normal initially, often worsens w/ rising INR despite transaminase improvement.</li><li>Prognosis: rapid clinical improvement w/ restored hemodynamic status; largely dictated by underlying condition.</li><li>LT not usually indicated or necessary.</li></ul>
                
        <details>
            <summary><strong>Management of Ischemic Liver Injury</strong></summary>
            <div>
                <ul><li>Largely supportive; aimed at correcting underlying cause &amp; restoring hemodynamic stability.</li><li>Vasopressor use: may be necessary to maintain satisfactory MAP.</li><li>NAC: 2 case reports suggest helpful in ischemic hepatitis (vascular obstruction or heat stroke).</li><li>ALFSG report (55 ALF patients due to ischemic hepatitis): 8 of 9 spontaneous survivors treated w/ NAC (needs larger numbers).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Malignant Infiltration</strong></summary>
            <div>
                <ul><li>Accounts for minority of ALF cases (1.4% in US ALFSG registry).</li><li>Etiologies: lymphoma/leukemia (33%), breast cancer (30%), colon cancer (7%).</li><li>Demographics: median age 47 years, mostly female (67%) &amp; White (67%).</li><li>Presentation: abdominal pain, jaundice, HE, hepatomegaly.</li><li>Labs: mixed hepatocellular &amp; cholestatic injury, markedly elevated transaminases (≈40× ULN), prolonged INR, thrombocytopenia.</li><li>Diagnosis: &lt;half had liver masses on imaging; typically relied on liver or bone marrow biopsy.</li><li>Prognosis: dismal; 85% die within 3 weeks.</li></ul>
                
        <details>
            <summary><strong>Management of Malignant Infiltration</strong></summary>
            <div>
                <ul><li>High suspicion required, esp. if malignancy undiagnosed.</li><li>Malignancy-directed treatment may be indicated.</li><li>LT generally not performed due to tumor infiltration &amp; poor patient outcome (only 2 reported cases in US ALFSG, 1 survived &gt;5 years).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Coronavirus 2019–Related Disease (COVID-19)</strong></summary>
            <div>
                <ul><li>Patients w/ COVID-19 frequently have elevated liver enzymes (hepatic injury).</li><li>Pattern: typically hepatocellular vs. cholestatic.</li><li>Liver injury multifactorial: direct viral cytotoxicity, immune-mediated damage, ischemic liver injury, thrombotic complications, endotheliitis, DILI.</li><li>Management: supportive.</li><li>Severity: generally mild, but severe hepatic dysfunction can develop w/ multiorgan failure.</li><li>LT generally not possible due to multiple comorbidities.</li><li>Optimal timing of LT in COVID-19 positive ALF patients unknown.</li><li>American Society of Transplantation: candidate should have complete symptom resolution (ideally negative COVID-19 PCR) before transplant.</li><li>Asymptomatic ALF patients w/ COVID-19: multidisciplinary approach to consider risks/benefits of transplant.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Indeterminate Etiology</strong></summary>
            <div>
                <ul><li>Clear etiology cannot be determined in some ALF instances.</li><li>US ALFSG: 5.5% eventually adjudicated as indeterminate.</li><li>Review: nearly half (46.9%) of previously indeterminate cases found to have an etiology (APAP 45, AIH 24, DILI, viruses like HEV, miscellaneous).</li><li>Liver biopsy may be warranted.</li><li>Steroid therapy: not found to improve survival in indeterminate cases.</li><li>NAC: consideration given due to evidence of ↑ TFS in non-APAP ALF w/ low-grade encephalopathy (stage 1–2).</li><li>Otherwise, patients should be considered for LT due to poor spontaneous survival.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Liver Transplantation (LT)</strong></summary>
            <div>
                <ul><li>Pre-LT era: ALF mortality approached 80%.</li><li>Advances in LT &amp; critical care: patient &amp; graft survival rates dramatically improved over 20 years.</li><li>Survival rates remain lower than for patients w/ cirrhosis.</li><li>1-year &amp; 5-year post-LT patient survival ≈80% &amp; 75% respectively.</li><li>Most deaths occur within months post-transplantation; long-term survival excellent otherwise.</li></ul>
                
        <details>
            <summary><strong>Prognostic Models</strong></summary>
            <div>
                <ul><li>Identifying patients w/ low chance of spontaneous recovery is paramount, esp. for initial assessment outside transplant center.</li><li>Encephalopathy development w/ acute liver injury → trigger transfer to transplant center.</li><li>APAP-induced ALF: particularly at risk of rapid clinical progression vs. non-APAP cases.</li></ul>
                
        <details>
            <summary><strong>King&#x27;s College Criteria (KCC)</strong></summary>
            <div>
                <ul><li>Most used prognostic model for predicting transplant-free survival.</li><li>Reported sensitivity/specificity: 68%/82% (non-APAP ALF), 65%/93% (APAP-induced ALF).</li><li>Addition of lactate improved KCC performance to 91% sensitivity.</li><li>Meta-analyses: good specificity but limited sensitivity → concerns about poor prediction of death w/o transplantation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Model for End-Stage Liver Disease (MELD)</strong></summary>
            <div>
                <ul><li>Evaluated in ALF in multiple studies.</li><li>Meta-analysis (23 studies, 2,153 patients) comparing MELD vs KCC:</li><li>MELD thresholds not standardized (25–37).</li><li>Pooled data: KCC had lower sensitivity for mortality than MELD (59% vs 74%), but slightly higher specificity (79% vs 67%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clichy Criteria</strong></summary>
            <div>
                <ul><li>Widely used in France, not popular in US.</li><li>Based on age, Factor V levels, presence of grade 3–4 HE.</li><li>Low specificity (56% for APAP-induced ALF, 50% for non-APAP-induced ALF) → not widely used.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>ALF Study Group Model</strong></summary>
            <div>
                <ul><li>Incorporates HE grade, ALF etiology, vasopressor use, bilirubin, INR.</li><li>Showed c-statistical value of 0.84.</li><li>Prospective validation needed.</li></ul>
                
        <details>
            <summary><strong>Key Concept: Prognostic Models</strong></summary>
            <div>
                <ul><li>Identifying ALF patients at risk of poor outcomes is important &amp; should trigger transfer to a transplant center early in presentation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendation: KCC or MELD for Prognostication</strong></summary>
            <div>
                <ul><li>In patients w/ ALF, recommend using either KCC or MELD score for prognostication.</li><li>Patients meeting KCC criteria or presenting w/ MELD &gt;25 are at high risk of poor outcomes.</li><li>GRADE: conditional, low quality of evidence.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Transplant Evaluation</strong></summary>
            <div>
                <ul><li>Transplant team (hepatology, surgery, psychiatry/social work) engaged promptly to guide evaluation &amp; management.</li><li>Team considers patient&#x27;s candidacy based on medical &amp; psychosocial factors.</li><li>Brain death: only absolute contraindication for LT.</li><li>Multiorgan dysfunction, sepsis, ARDS, pancreatitis, cancer: relative contraindications.</li><li>Decisions made in multidisciplinary discussion.</li></ul>
                
        <details>
            <summary><strong>Alcohol Use Disorder Recurrence</strong></summary>
            <div>
                <ul><li>No studies specifically address recurrence in ALF patients.</li><li>Great heterogeneity in center-specific protocols for psychosocial assessment &amp; alcohol abstinence requirements.</li><li>Efforts to gather collateral information from family/friends to inform decision regarding post-transplant alcohol-related liver disease risk.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Key Concept: Multidisciplinary Discussion</strong></summary>
            <div>
                <ul><li>Multidisciplinary discussion involving the transplant team to determine individual transplant candidacy should be undertaken at the transplant center.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Graft Considerations (Living Donor and ABO-Incompatible Grafts)</strong></summary>
            <div>
                <ul><li>Most status 1A patients receive timely organ offer, but 18.2% died or became too sick for transplantation (UNOS database).</li><li>Led to consideration of living donor grafts &amp; ABO-incompatible deceased organ grafts.</li></ul>
                
        <details>
            <summary><strong>Living Donor Liver Transplantation (LDLT)</strong></summary>
            <div>
                <ul><li>Concerns: limited time for donor evaluation, informed consent (minimize coercion), donor safety.</li><li>Systematic review (3 studies, 2,533 adult ALF patients): 155 underwent LDLT.</li><li>Comparison of LDLT w/ DDLT: no significant differences in survival at 1, 3, &amp; 5 years.</li><li>UNOS database (since 2011): only 3 patients, confirming not widely practiced.</li></ul>
                
        <details>
            <summary><strong>Key Concept: LDLT in ALF</strong></summary>
            <div>
                <ul><li>In patients w/ ALF, listed as status 1A priority, LDLT may be considered in centers w/ LDLT experience when DDLT is not readily available.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>ABO-Incompatible (ABO-I) Grafts</strong></summary>
            <div>
                <ul><li>Described w/ living &amp; deceased donors (mostly observational retrospective studies).</li><li>Two observational studies (China n=22, Norway n=33): showed inferior graft, patient survival, &amp; ↑ risk of antibody-mediated rejection.</li><li>Earlier study (China n=33): noninferior 3-year patient &amp; graft survival w/ only 2 rejections.</li><li>Significant heterogeneity in immunosuppressive regimens across studies.</li><li>Data from 2000s; medical supportive care &amp; ABO-I protocols (rituximab) have since improved.</li></ul>
                
        <details>
            <summary><strong>Key Concept: ABO-I Grafts in ALF</strong></summary>
            <div>
                <ul><li>In patients w/ ALF, listed as status 1A priority, suggest consideration of ABO-I grafts in a rapidly declining patient.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Experimental Procedures</strong></summary>
            <div>
                <ul><li>Procedures not routinely recommended due to paucity of evidence.</li></ul>
                
        <details>
            <summary><strong>Two-Staged Liver Transplantation</strong></summary>
            <div>
                <ul><li>Involves hepatectomy, portocaval shunt formation, prolonged anhepatic state while awaiting organ.</li><li>Not routinely recommended in ALF patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Auxiliary Orthotopic Liver Graft (APPOLT)</strong></summary>
            <div>
                <ul><li>Surgical practice of adding auxiliary partial/whole liver graft alongside recipient&#x27;s native liver to support regeneration.</li><li>Predominantly used in children; several reports in adult ALF w/ living &amp; deceased donor grafts.</li><li>Reported outcomes mixed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>ALF is a medical emergency, potentially reversible if recognized &amp; treated early.</li><li>Must be differentiated from ACLF &amp; decompensated cirrhosis (management vastly different).</li><li>Affects multiple organs &amp; carries high short-term mortality.</li><li>Timely transfer to transplant center is a priority early in patient management.</li><li>Patients at high risk of death have excellent prognosis after lifesaving LT.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
